Archives
What High-Yield Rabbit Pharming Evidence Shows
2026-11-04
A targeted rabbit line produced markedly higher reporter-protein concentrations in milk than historical conventional lines, but the evidence remains a small proof-of-concept rather than a controlled demonstration of general therapeutic-production performance.
Diminazene Aceturate in ACE2 Cardiomyopathy Research
2026-11-03
A preclinical study used Diminazene Aceturate as a pharmacological probe of ACE2 signaling in sepsis-induced cardiomyopathy. The findings support a protective association involving the ACE2–MasR–Sirt1 axis and mitochondrial biogenesis, while leaving target specificity, causal ordering and clinical relevance unresolved.
Why the CSN2 Locus Raised Rabbit Pharming Yield
2026-11-03
A targeted integration strategy placed a reporter gene under the control of the rabbit CSN2 milk-protein promoter. The resulting line reached 15–20 g/L tdTomato in milk from two homozygous females, while the study’s design and limited animal-level evidence leave important questions about reproducibility, product quality, and transferability to therapeutic proteins.
From CSN2 Targeting to Rabbit Pharming Yield
2026-11-02
A literature-focused analysis of how targeted insertion at the rabbit CSN2 locus was linked to high tdTomato concentrations in milk, and what the study does—and does not—establish about animal pharming.
When Context Changes a Biological Yield
2026-11-02
A high milk concentration can demonstrate strong expression in a particular genetic and physiological context without establishing therapeutic performance, manufacturing consistency, or broad applicability.
A CSN2-Targeted Strategy for Rabbit Pharming
2026-11-01
A literature-focused analysis of a 2025 study that used targeted insertion at the rabbit CSN2 milk-protein locus to increase recombinant reporter production, with emphasis on mechanism, comparative evidence, and limits to translation.
Why Rabbit Mammary-Locus Targeting Matters
2026-10-31
A 2025 study tested whether placing a recombinant reporter gene at the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenesis. The resulting line transmitted the targeted allele and produced reported milk concentrations of 15–20 g/L in homozygous animals, while important questions remain about therapeutic-protein generalizability, total recoverable output, animal performance, and long-term line validation.
Why the CSN2 Locus Raised Rabbit Milk Yield
2026-10-30
A targeted rabbit line used the endogenous CSN2 milk-protein regulatory context to drive tdTomato expression, producing a reported 15–20 g/L in milk from two homozygous females. The result supports a mechanistic role for locus selection and mammary-specific regulation, but it does not yet establish equivalent performance for therapeutic proteins or across broader rabbit populations.
What High-Yield Rabbit Pharming Evidence Shows
2026-10-30
A 2025 study reported substantially higher milk production of a fluorescent recombinant protein after targeted insertion at the rabbit CSN2 locus. The result supports a strong locus-and-promoter hypothesis, but its generality across therapeutic proteins, animals, and production settings remains unresolved.
When Context Changes What a Result Means
2026-10-29
A mechanistic mouse study shows how genotype, tissue injury, cellular readouts, and clinical correlation can shift the interpretation of the same biological result. The associated Mouse Tissue Lysis Kit K1038 belongs to the upstream genotyping layer, while the study’s mechanistic conclusions depend on macrophage, lysosomal, and infection-related measurements.
What High-Yield Rabbit Pharming Evidence Shows
2026-10-29
A critical reading of a 2025 rabbit line study finds a striking milk-protein concentration result, but also shows why the evidence does not yet isolate promoter effects, establish therapeutic-protein performance, or replace direct comparative validation.
How a DGAT1 Inhibitor Changes Lipid Readouts
2026-10-28
DGAT1 inhibition is best interpreted as a target-proximal perturbation of triglyceride biosynthesis. Comparing triglyceride and diacylglycerol pools can clarify whether a lipid change is consistent with reduced terminal synthesis, while catalog characterization alone does not establish cellular potency, selectivity, or disease benefit.
AS1842856 in the Iron–KDM4D–Foxo1 Axis
2026-10-27
The reported mouse and mesenchymal-stem-cell study places AS1842856 downstream of an iron-sensitive KDM4D–PIK3R3–PI3K–Akt circuit. Its findings support Foxo1 activity as a functional regulator of quiescent-cell activation, while leaving selectivity, target engagement, and translation beyond this model unresolved.
Rabbit Pharming and the CSN2 Promoter Mechanism
2026-10-27
A 2025 study reported 15–20 g/L of a fluorescent reporter in milk from homozygous knock-in rabbits by combining targeted genomic insertion with the endogenous CSN2 milk-protein promoter. The result supports a mechanistic proof of concept for locus-aware expression, but cross-study comparisons, reporter biology, animal number and concentration-only measurement limit broader conclusions.
How Maresin 1 Relates to Inflammation Resolution
2026-10-26
Maresin 1 is best interpreted as a lipid mediator associated with the biology of inflammation resolution. A useful research question is how a molecular signal becomes a cellular and tissue-level readout—and why reduced inflammation alone does not prove active resolution.